Which statement about hydralazine plus isosorbide dinitrate in heart failure is true?

Which statement about hydralazine plus isosorbide dinitrate in heart failure is true?

• A. It has no clinical benefit in any patient group.
• B. It has shown mortality benefit when added to standard therapy in symptomatic Black patients.
• C. It worsens outcomes in Black patients.
• D. It has no role in heart failure management.

Answer: (B)

The main idea is that this drug combination improves outcomes in a specific heart failure population. Hydralazine reduces arterial afterload while isosorbide dinitrate lowers preload by venodilation, so together they improve the heart’s workload and oxygen balance. When added to standard heart failure therapy, this duo has been shown to reduce mortality and hospitalizations specifically in symptomatic Black patients. The key evidence comes from a large trial in which Black patients with advanced heart failure on optimal therapy experienced a survival benefit with the combination versus placebo. This benefit is not consistently seen in other racial groups, so the regimen is recommended as an additional option for Black patients who remain symptomatic despite standard therapy. It is not accurate to say there is no role or no benefit, or that it worsens outcomes in this subgroup, since the trial demonstrated improved outcomes in that population.

The main idea is that this drug combination improves outcomes in a specific heart failure population. Hydralazine reduces arterial afterload while isosorbide dinitrate lowers preload by venodilation, so together they improve the heart’s workload and oxygen balance. When added to standard heart failure therapy, this duo has been shown to reduce mortality and hospitalizations specifically in symptomatic Black patients. The key evidence comes from a large trial in which Black patients with advanced heart failure on optimal therapy experienced a survival benefit with the combination versus placebo. This benefit is not consistently seen in other racial groups, so the regimen is recommended as an additional option for Black patients who remain symptomatic despite standard therapy. It is not accurate to say there is no role or no benefit, or that it worsens outcomes in this subgroup, since the trial demonstrated improved outcomes in that population.